Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder
Open accessThe DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index; none of the 150 sources its claims cite is checked for support yet.
Abstract
There is a substantial body of literature documenting the efficacy of multiple unrelated pharmacological agents in attention-deficit hyperactivity disorder (ADHD) individuals throughout the life-cycle. The available literature indicates the important role of psychopharmacological agents in the reduction of the core symptoms of ADHD and associated impairments. The literature documents that stimulants not only improve abnormal behaviours of ADHD, but also improves self-esteem, cognition, and social and family function. However, response varied in different age groups and with certain comorbidities. In addition there is a large body of literature documenting the efficacy of atomoxetine which shows improvement in these same domains. More research is needed on alternative pharmacological treatments and to further evaluate established therapeutics beyond school-aged Caucasian boys. Further, more research is needed on the efficacy of treatment for comorbid ADHD, use of combined medications, and the combination of medication and psychosocial treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 11 Not valid · 113 Not checked · 48 Own results and interpretations
In the paper
“Although less commonly reported, mood disturbances ranging from increased tearfulness to a full-blown major depression-like syndrome can be associated with stimulant treatment (Wilens and Biederman, 1992).”
§ Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder > Stimulant drugs
What the sources say
- Not checked yetcites Wilens and Biederman, 1992
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most commonly reported side-effects associated with the administration of stimulant medication are appetite suppression and sleep disturbances.”
§ Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder > Stimulant drugs
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“While it was originally thought that individuals with ADHD inevitably outgrew the disorder, converging evidence from longitudinal, retrospective and crosssectional studies has revealed that the majority of children with ADHD continue to have significant ADHD-associated impairment as adults (Spencer et al., 1998c).”
§ Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder > Adult ADHD
What the sources say
- Not checked yetcites Spencer et al., 1998c
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The early concern that optimal clinical efficacy is attained at the cost of impaired learning ability has not been confirmed (Gittleman-Klein, 1987).”
§ Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder > Stimulant drugs
What the sources say
- Not checked yetcites Gittleman-Klein, 1987
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There is a substantial body of literature documenting the efficacy of multiple unrelated pharmacological agents in attention-deficit hyperactivity disorder (ADHD) individuals throughout the life-cycle.”
§ Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
80 more claims
Create a free account to see all 172 claims and to verify the 150 references still open.
- It may state two separate claims as one. 75
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stimulants are effective in about 70% of patients with ADHD in controlled studies [265-267] depending on the study design and maximum drug dosage.”
From European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD (2010) · cites this paper as [266]
Experimental — accuracy not yet measured
Citations
Cites
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation
Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan, C. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710233371703 · Cited by 1,261
Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder
Castellanos, F. X. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830070053009 · Cited by 1,183
Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Goldman, L. S. (1998) · JAMA · doi:10.1001/jama.279.14.1100 · Cited by 1,082
Cerebral Glucose Metabolism in Adults with Hyperactivity of Childhood Onset
Zametkin, A. J., Nordahl, T. E., Gross, M., King, A. C., Semple, W. E., Rumsey, J., Hamburger, S., & Cohen, R. M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232001 · Cited by 969
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Self-citationNeurobiology of attention-deficit hyperactivity disorder
Faraone, S. V., & Biederman, J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00240-6 · Cited by 811
Self-citationBiederman, J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820090056010 · Cited by 771
Self-citationMichelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Self-citationScahill, L., Chappell, P. B., Kim, Y. S., Schultz, R. T., Katsovich, L., Shepherd, E., Arnsten, A. F. T., Cohen, D. J., & Leckman, J. F. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1067 · Cited by 588
Research works printed but not linked: 13
- Arnold L (2000). Methylphenidate vs. amphetamine: comparative review. Journal of Attention Disorders 3, 200-211.
- Bergman A, Winters L, Cornblatt B (1991). Methylphenidate: effects on sustained attention. In: Greenhill L, Osman B (Eds.), Ritalin: Theory and Patient Management (pp. 223-231). New York : Mary Ann Liebert Inc.
- Biederman J, Milberger S, Faraone S, Kiely K, Guite J, Mick E, Ablon S, Warburton R, Reed E (1994). Family environmental risk factors for attention deficit hyper- activity disorder: a test of Rutter's indicators of adversity. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry.
- Findling R, Schwartz M, Flannery D, Manos M (1996). Venlafaxine in adults with ADHD: an open trial. Journal of Clinical Psychiatry 57, 184-189.
- Gittleman R (1980). Childhood Disorders. In : Klein D, Quitkin F, Rifkin A, Gittleman R (Eds.), Drug Treatment of Adult and Child Psychiatric Disorders (pp. 576-756).
- Gittleman-Klein R (1974). Pilot clinical trial of imipramine in hyperkinetic children. In: Conners CK (Ed.), Clinical Use of Stimulant Drugs in Children (pp. 192-201). The Hague, Netherlands: Excerpta Medica.
- Gittleman-Klein R (1987). Pharmacotherapy of childhood hyperactivity: an update. In : Meltzer HY (Eds.), Psycho- pharmacology : The Third Generation of Progress (pp. 1215-1224). New York : Raven Press.
- Pomerleau O, Downey K, Stelson F, Pomerleau C (1995). Cigarette smoking in adult patients diagnosed with ADHD. Journal of Substance Abuse 7, 373-378.
- Prince J, Wilens T, Biederman J, Spencer T, Wozniak J (1996). Clonidine for ADHD related sleep disturbances: a systematic chart review of 62 cases. Journal of the American Academy of Child and Adolescent Psychiatry 35, 599-605.
- Spencer T, Biederman J, Kerman K, Steingard R, Wilens T (1993a). Desipramine in the treatment of children with Tic disorder or Tourette's Syndrome and attention deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 32, 354-360.
- Spencer T, Biederman J, Wilens T (1997). Pharmacotherapy of ADHD: a life span perspective. In: Oldham J, Riba M (Eds.), American Psychiatric Press Review of Psychiatry (pp. 87-128). Washington, DC : American Psychiatric Association.
- Swanson J, Agler D, Fineberg E, Wigal S, Flynn D, Fineberg K, Quintana Y, Talebi H (2000). University of California, Irvine, laboratory school protocol for pharmacokinetic and pharmacodynamic studies. In : Greenhill L, Osman BB (Eds.), Ritalin: Theory and Practice, 2nd edn (pp. 405-430).
- Zametkin AJ, Rapoport JL (1987). Noradrenergic hypothesis of attention deficit disorder with hyperactivity : a critical review. In : Meltzer HY (Ed.), Psychopharmacology : The Third Generation of Progress (pp. 837-842). New York: Raven Press.
Cited by
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
“Atomoxetine is preferred if the patient experiences severe side effects to stimulants such as mood lability or tics (Biederman et al., 2004).”
BackgroundKooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“Stimulants are effective in about 70% of patients with ADHD in controlled studies [265-267] depending on the study design and maximum drug dosage.”
Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573
Treatment Guidelines for Children and Adolescents With Bipolar Disorder
KOWATCH, R. A., FRISTAD, M., BIRMAHER, B., WAGNER, K. D., FINDLING, R. L., & HELLANDER, M. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200503000-00006 · Cited by 455
“Currently, the medications used to treat ADHD include the stimulants (methylphenidate and derivatives of amphetamine) and nonstimulants (atomoxetine, bupropion, the tricyclic antidepressants), and to a lesser extent the a2-agonists (clonidine and guanfacine) (Biederman et al., 2004).”
BackgroundWolraich, M. L., Wibbelsman, C. J., Brown, T. E., Evans, S. W., Gotlieb, E. M., Knight, J. R., Ross, E. C., Shubiner, H. H., Wender, E. H., & Wilens, T. (2005) · Pediatrics · doi:10.1542/peds.2004-1959 · Cited by 404
Self-citation
Metadata
- Authors
- Biederman, J., Spencer, T., & Wilens, T.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Biederman, Joseph
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-03
- Volume
- 7
- Issue
- 1
- Pages
- 77-97
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2058706567
- Cited by
- 253
- References
- 140
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 3 · 2020: 59 · 2019: 5 · 2018: 7 · 2017: 3 · 2016: 8 · 2015: 9 · 2014: 9 · 2013: 15 · 2012: 12
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Massachusetts General Hospital
- National Institutes of Health
- National Institute of Mental Health (R01MH050657, 5R29MH575105, 5R01MH50657-10)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD036317, 5R01HD36317-05)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
- Keywords
- attention deficit hyperactivity disorder, ADHD medication, stimulant medication, atomoxetine, ADHD comorbidity, self-esteem, cognitive function, age differences in treatment response
- MeSH terms
- Atomoxetine Hydrochloride, Adrenergic alpha-Agonists, Adult, Central Nervous System Stimulants, Antidepressive Agents, Attention Deficit Disorder with Hyperactivity, Child, Clonidine, Delayed-Action Preparations, Humans, Methylphenidate, Propylamines, Guanfacine, Bupropion, Antidepressive Agents, Second-Generation, Adrenergic Uptake Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. https://app.cochat.ai/papers/10.1017/s1461145703003973
- The paper
- Biederman, J., Spencer, T., & Wilens, T. (2004). Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145703003973
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.